{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.07"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"133"}],"units":"Participants"}],"description":"The population pharmacokinetic (PopPK) model of trametinib can be described using a two-compartment model with dual sequential 1st order absorption (Ka1, Ka2) and 1st order elimination. Apparent clearance (CL/F) of trametinib estimated with the PopPK model is summarized in this record.","groups":[{"description":"Participants in the study (all doses and all tumor types) with available pharmacokinetic data","id":"OG000","title":"Part A, B, C and D - All Participants With PK Data"}],"paramType":"NUMBER","populationDescription":"All subjects who received at least one dose of trametinib in Part A, B, C and D and provided an evaluable PK profile. All trametinib and dabrafenib concentration-time data were combined and included in a population PK analysis that examined the influence of demographics on the PK of study treatment.","reportingStatus":"POSTED","timeFrame":"pre dose, 1, 2, 4, 7, 10 and 24 hours post trametinib dose on Cycle 1 Day 15 (part A and B) and pre dose, 0.5, 1, 2, 3, 4, 6 and 8 hours post trametinib dose on Cycle 1 Day 15 (part C and D). The duration of 1 cycle was 28 days.","title":"Apparent Clearance (CL/F) of Trametinib Estimated With a PopPK Model","type":"SECONDARY","unitOfMeasure":"liters/hour"}